The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Type I interferons (IFN-I) are key innate immune effectors against pathogens.
• IFN-I induction is triggered by nucleic acid sensing via pattern-recognition receptors.
• IFN-I signaling reprograms cellular states through JAK-STAT and noncanonical pathways.

Purpose of the Study:

• To explore the regulatory mechanisms of the IFN-I axis.
• To understand the role of IFN-I dysregulation in autoimmune diseases.
• To highlight therapeutic strategies targeting the IFN-I pathway.

Main Methods:

• Review of current literature on IFN-I biology and autoimmune diseases.
• Analysis of IFN-I signaling pathways, including JAK-STAT and noncanonical routes.
• Examination of epigenetic regulation and its impact on IFN-I activity.

Main Results:

• IFN-I dysregulation is implicated in autoimmune disorders such as systemic lupus erythematosus (SLE).
• IFN-responsive gene signatures can stratify SLE endotypes and predict treatment response.
• Therapeutic interventions like anti-IFN-I receptor therapy and JAK inhibition are emerging.

Conclusions:

• A comprehensive understanding of the IFN-I axis is vital for immune-mediated diseases.
• This knowledge facilitates patient stratification and personalized therapy design.
• Targeting the IFN-I pathway offers promising therapeutic avenues.